Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

488
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
488
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

613
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
613
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

503
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
503
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

743
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
743

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of wheatgrass (<i>Triticum aestivum</i>) preparation in regulation of antigen presentation through the immunomodulation and epigenetic modification in acute leukemia.

3 Biotech·2026
Same author

Utility of miRNA biomarkers in patients with acute myocardial infarction (UNIAMI)-results from a prospective pilot study.

Frontiers in cardiovascular medicine·2026
Same author

Role of novel renal biomarkers in predicting the prognosis of patients with chronic kidney disease: a prospective cohort study.

Turkish journal of medical sciences·2026
Same author

Retraction notice to "Immunomodulatory Role of Diospyros peregrina Fruit Preparation in Breast Cancer by Utilizing Macrophage Mediated Antigen Presentation and T Helper Cell (Th) Differentiation" [Clinical Breast Cancer 23 (2023) e95-e102].

Clinical breast cancer·2026
Same author

Exploratory Analysis of MicroRNA (miRNA) as a Prognostic and Predictive Biomarker in Locally Advanced and Metastatic Gastric Cancer.

Cureus·2026
Same author

Diving into the Regulatory Landscape of Digital Therapeutics.

Therapeutic innovation & regulatory science·2026

Related Experiment Video

Updated: Mar 6, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

End points in heart failure-are we doing it right?

Luxitaa Goenka1, Melvin George2, Sandhiya Selvarajan3

  • 1Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre, SRM Nagar, Potheri, Kattankulathur, Chennai, 603203, Tamil Nadu, India.

European Journal of Clinical Pharmacology
|March 11, 2017
PubMed
Summary

Identifying common heart failure (HF) trial endpoints is crucial. This study analyzes phase 3 clinical trial endpoints for acute and chronic heart failure to guide future drug development.

Keywords:
Acute heart failureChronic heart failureComposite end pointDyspneaPrimary end points

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Experiment Videos

Last Updated: Mar 6, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Area of Science:

  • Cardiology
  • Clinical Trials
  • Drug Development

Background:

  • Heart failure (HF) presents significant mortality and morbidity challenges.
  • Effective drug development for HF requires robust clinical trial designs.

Purpose of the Study:

  • To identify and analyze the most frequent endpoints used in Phase III heart failure clinical trials.
  • To discuss the advantages and disadvantages of these common endpoints.

Main Methods:

  • Literature review of randomized clinical trials (RCTs) for heart failure from 2010-2016.
  • Data extraction focused on primary endpoints from selected trials.
  • Identification of recurrent and significant endpoints in Phase III HF trials.

Main Results:

  • Common endpoints for acute heart failure (AHF) include composite endpoints, dyspnea, and cardiovascular (CV) death.
  • Chronic heart failure (CHF) trials frequently used composite endpoints, 6-minute walk test (6MWT), CV death or heart failure hospitalization (HFH), Vo2 max, all-cause mortality, left ventricular ejection fraction (LVEF), and dyspnea.

Conclusions:

  • The selection of appropriate endpoints is critical for successful HF drug development.
  • Optimizing endpoint selection can accelerate the delivery of effective therapies to patients.
  • Standardizing endpoints may improve the efficiency and reliability of HF clinical trials.